Pharmacological disruption of the MID1/α4 interaction reduces mutant Huntingtin levels in primary neuronal cultures

Olivia Monteiro, Changwei Chen, Ryan Bingham, Argyrides Argyrou, Rachel Buxton, Christina Pancevac Jönsson, Emma Jones, Angela Bridges, Kelly Gatfield, Sybille Krauß, Jeremy Lambert, Rosamund Langston, Susann Schweiger, Iain Uings (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)
    613 Downloads (Pure)

    Abstract

    Expression of mutant Huntingtin (HTT) protein is central to the pathophysiology of Huntington’s Disease (HD). The E3 ubiquitin ligase MID1 appears to have a key role in facilitating translation of the mutant HTT mRNA suggesting that interference with the function of this complex could be an attractive therapeutic approach. Here we describe a peptide that is able to disrupt the interaction between MID1 and the α4 protein, a regulatory subunit of protein phosphatase 2A (PP2A). By fusing this peptide to a sequence from the HIV-TAT protein we demonstrate that the peptide can disrupt the interaction within cells and show that this results in a decrease in levels of ribosomal S6 phosphorylation and HTT expression in cultures of cerebellar granule neurones derived from HdhQ111/Q7 mice. This data serves to validate this pathway and paves the way for the discovery of small molecule inhibitors of this interaction as potential therapies for HD.
    Original languageEnglish
    Pages (from-to)44-50
    Number of pages7
    JournalNeuroscience Letters
    Volume673
    Early online date27 Feb 2018
    DOIs
    Publication statusPublished - 23 Apr 2018

    Keywords

    • Huntington's Disease
    • MID1
    • Cerebellar granule cell culture

    Fingerprint

    Dive into the research topics of 'Pharmacological disruption of the MID1/α4 interaction reduces mutant Huntingtin levels in primary neuronal cultures'. Together they form a unique fingerprint.

    Cite this